Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy Sells 59,925 Shares

Key Points

• Adam Scott Levy, CFO of Mineralys Therapeutics, sold a total of 59,925 shares of the company's stock at an average price of $14.76, totaling approximately $884,493, which represented a 31.07% decrease in his ownership.
• Mineralys Therapeutics shares saw an increase of 4.4% to reach $14.49, with a market capitalization of $944.46 million and a reported P/E ratio of -3.88.
• Wall Street analysts have mixed ratings on Mineralys Therapeutics, with one analysis rating it as a "sell," while others have set target prices ranging from $15.00 to $48.00, maintaining an average target of $32.25.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CFO Adam Scott Levy sold 59,925 shares of Mineralys Therapeutics stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $14.76, for a total value of $884,493.00. Following the transaction, the chief financial officer owned 132,934 shares in the company, valued at $1,962,105.84. This trade represents a 31.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Adam Scott Levy also recently made the following trade(s):

• On Tuesday, July 29th, Adam Scott Levy sold 807 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $14.00, for a total value of $11,298.00.
• On Monday, July 28th, Adam Scott Levy sold 12,946 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $14.04, for a total value of $181,761.84.
• On Friday, July 11th, Adam Scott Levy sold 10,758 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $14.45, for a total value of $155,453.10.

Mineralys Therapeutics Stock Down 3.5%

NASDAQ MLYS traded down $0.49 during trading hours on Friday, hitting $13.66. 1,107,843 shares of the company were exchanged, compared to its average volume of 637,447. The stock has a 50-day moving average price of $14.52 and a 200 day moving average price of $13.27. Mineralys Therapeutics, Inc. has a 52 week low of $8.24 and a 52 week high of $18.38. The stock has a market cap of $890.36 million, a PE ratio of -3.66 and a beta of -0.29.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.79) EPS for the quarter, beating analysts' consensus estimates of ($1.02) by $0.23. As a group, sell-side analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on MLYS shares. Wall Street Zen downgraded Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. HC Wainwright restated a "buy" rating and issued a $42.00 price objective on shares of Mineralys Therapeutics in a research report on Tuesday, June 17th. Guggenheim set a $48.00 price objective on Mineralys Therapeutics and gave the company a "buy" rating in a research report on Wednesday, May 14th. Finally, Jefferies Financial Group initiated coverage on Mineralys Therapeutics in a research report on Tuesday, June 10th. They issued a "hold" rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $32.25.

Institutional Trading of Mineralys Therapeutics

A number of large investors have recently modified their holdings of the company. Wellington Management Group LLP lifted its holdings in Mineralys Therapeutics by 43.0% during the fourth quarter. Wellington Management Group LLP now owns 91,529 shares of the company's stock worth $1,127,000 after buying an additional 27,531 shares during the period. Dimensional Fund Advisors LP acquired a new position in shares of Mineralys Therapeutics during the fourth quarter worth $202,000. GAMMA Investing LLC increased its position in shares of Mineralys Therapeutics by 9,602.2% during the first quarter. GAMMA Investing LLC now owns 8,829 shares of the company's stock worth $140,000 after purchasing an additional 8,738 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Mineralys Therapeutics during the fourth quarter worth $48,000. Finally, JPMorgan Chase & Co. increased its position in shares of Mineralys Therapeutics by 2,251.5% during the fourth quarter. JPMorgan Chase & Co. now owns 503,590 shares of the company's stock worth $6,199,000 after purchasing an additional 482,174 shares in the last quarter. Hedge funds and other institutional investors own 84.46% of the company's stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.